A search of the literature revealed that CD44 was required for SRGN to promote aggressiveness of non-small cell lung cancer 41, and that CD44-positive prostate cancer cells were significantly more susceptible to the inhibitory effect of MDK-knockdown on cell viability 42. Here, CD44 is linked to non-small cell lung carcinoma.